Form 4: Harrow Inc. CEO John P. Saharek Reports Stock Transactions Following PSU Vesting

John P. Saharek, CEO & President of ImprimisRx at Harrow Inc., reports acquisition and disposal of common stock related to performance stock units (PSUs) vesting.

Summary

• On April 3, 2025, John P. Saharek vested 277,200 shares of Harrow Inc. common stock upon the vesting of performance stock units (PSUs) granted on April 3, 2023.
• The PSUs vested after a two-year service period and achievement of Harrow common stock price targets between $25 and $50.
• On April 7, 2025, the vested PSUs were settled in shares of Harrow common stock on a one-for-one basis.
• Also on April 7, 2025, 109,475 shares were withheld by Harrow for payroll tax purposes related to the PSU vesting.
• Following these transactions, Saharek directly owns 467,388 shares of Harrow common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the vesting of PSUs suggests the achievement of performance targets, but the document primarily reports transactions.

Positives

• The vesting of PSUs indicates that performance targets related to Harrow's stock price were met, suggesting positive company performance.

Industry Context

Executive compensation through stock options and PSUs is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.

Stakeholder Impact

• The vesting of PSUs and subsequent stock ownership changes may have a minor impact on shareholder value and perception.

Key Dates

Keywords

Harrow Inc., John P. Saharek, Performance Stock Units, PSUs, Stock Vesting, Beneficial Ownership, Form 4, HROW